Conversely, giving the drug at night or combining it with the immune checkpoint inhibitor anti-PD1 reverses or negates SHP2 inhibitor–mediated tumor shrinkage by changing monocyte and macrophage phenotypes rather than T-cell frequency. Here, PDCD1 is linked to neoplasm.